On 23 March 2018, Clinical Research Malaysia (CRM) and Japanese contract research organization intellim Corporation had signed a memorandum of understanding (MoU) in Tokyo to establish a new strategic partnership in clinical research.

The MoU was signed between the Chief Executive Officer (CEO) of CRM, Dr Akhmal Yusof and the President and CEO of intellim Corporation, Masakuni Ukita, witnessed by the Malaysian ambassador to Japan, Dato’ Ahmad Izlan Idris.

This signing was part of CRM’s efforts to reach out to foreign players in the clinical research field, in line with the current Malaysian Economic Transformation Programme (ETP) that targets clinical research as one of the main drivers in economic growth.

In a joint statement, intellim Corporation and CRM stated that the inking of the MoU spelt out support on clinical research activities in both Malaysia and Japan, as well as on business development and networking opportunities for both organisations.

The cooperation between both parties can result in an inflow of more clinical trials into Malaysia in the next few years. MIMS

For more on the latest medical news, clinical reference and e-learning modules, sign up now for a FREE MIMS account.

Read more:
WHO commends Malaysia’s medical research work
Research pharmacists are a growing career prospect in Malaysia
Moving medical research forward: Malaysia aims for 1,000 clinical trials by 2020

News report from Bernama